Left ventricular thrombosis
Conditions
Interventions
Experimental group:Rivaroxaban 15 mg
Control group:Starting warfarin 2.5 mg qd, adjusting warfarin dosage to stabilize PT-INR at 2.0-3.0
Sponsors
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 18 to 75 years old; 2. Sign informed consent; 3. LVT was diagnosed by TTE, cardiac CT or MRI.
Exclusion criteria
Exclusion criteria: 1. Cardiac causes: I. Moderate to severe mitral stenosis; II. After artificial valve implantation; III. Left atrial myxoma; IV. Infective endocarditis. 2. Causes of bleeding: I. Active intracranial hemorrhage; II. There was a history of bleeding or a high risk of bleeding in the past 30 days; III. Platelet count 3 × The maximum limit; VI. Complicated with severe infection; VII.BMI<18kg/m2 4. Reasons for combined use of drugs: I. Platelet IIb / IIIa receptor antagonist was used intravenously within 5 days; II. Thrombolytic agents were used within 10 days; III. Long term use of NSAIDs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete dissolution rate of LVT on the 90th dayombosis at day 90; | — |
Secondary
| Measure | Time frame |
|---|---|
| Dissolution percentage and dissolution time of LVT on the 90th day; | — |
Countries
China
Contacts
Public ContactShuanglun Xie
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Outcome results
None listed